References
- Chen C, Shi C, Huang X, et al. Molecular profiles and metastasis markers in Chinese patients with gastric carcinoma. Sci Rep. 2019;9(1):13995.31570735
- Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–456.25894828
- Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta. 1986;45(11–12):1363–1374.
- Lah TT, Babnik J, Schiffmann E, Turk V, Skaleric U. Cysteine proteinases and inhibitors in inflammation: their role in periodontal disease. J Periodontol. 1993;64(5 Suppl):485–491.8315571
- Saitoh E, Kim HS, Smithies O, Maeda N. Human cysteine-proteinase inhibitors: nucleotide sequence analysis of three members of the cystatin gene family. Gene. 1987;61(3):329–338.3446578
- Jiang J, Liu HL, Liu ZH, Tan SW, Wu B. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumour Biol. 2015;36(5):3903–3910.25577248
- Jiang J, Liu HL, Tao L, et al. Let7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway. Int J Oncol. 2018;53(2):781–790.29845224
- Yoneda K, Iida H, Endo H, et al. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol. 2009;35(1):33–40.19513549
- Cao X, Li Y, Luo RZ, et al. Expression of Cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients. Sci Rep. 2015;5:8230.25648368
- Dai DN, Li Y, Chen B, et al. Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis. J Mol Med (Berl). 2017;95(8):873–886.28523467
- Choi EH, Kim JT, Kim JH, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clin Chim Acta. 2009;406(1–2):45–51.19463800
- Hnasko TS, Hnasko RM. The western blot. Methods Mol Biol. 2015;1318:87–96.26160567
- Cai J, Guan H, Fang L, et al. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013;123(2):566–579.23321667
- Clements WM, Wang J, Sarnaik A, et al. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62(12):3503–3506.12067995
- Wang H, Deng G, Ai M, et al. Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/beta-catenin signaling pathways in gastric cancer progression. Oncogene. 2019;38(9):1489–1507.30305727
- Kang MH, Choi H, Oshima M, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nat Commun. 2018;9(1):1920.29765046